Trial Profile
A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 May 2019
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Intestinal infections
- Focus Diagnostic use
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 13 Apr 2015 New trial record
- 01 Oct 2014 Endpoint has been met (SUVmax of FDG in each colonic segment), according to results published in the Nuclear Medicine Communications.